Trial Profile
Prospective Observational Study on Stelara Assessing Efficacy and Healthcare Resource Utilization in Crohn's Disease (PROSE)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Feb 2022
Price :
$35
*
At a glance
- Drugs Ustekinumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms PROSE
- Sponsors Janssen-Cilag
- 26 Jan 2021 Status changed from active, no longer recruiting to completed.
- 05 Nov 2020 Planned End Date changed from 21 Nov 2021 to 29 Jan 2021.
- 05 Nov 2020 Planned primary completion date changed from 30 Sep 2020 to 29 Jan 2021.